Vitamin K antagonists and cognitive impairment: results from a cross-sectional pilot study among geriatric patients.

Autor:	Annweiler C; Department of Neuroscience, Division of Geriatric Medicine, UPRES EA4638, UNAM, Angers University Hospital, France. Robarts Research Institute, The University of Western Ontario, London, Canada. CeAnnweiler@chu-angers.fr., Ferland G; Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Quebec, Canada., Barberger-Gateau P; Centre INSERM U897-Epidemiologie-Biostatistique, ISPED, Université Bordeaux, France. Centre INSERM U897-Epidemiologie-Biostatistique, INSERM, ISPED, Bordeaux, France., Brangier A; Department of Neuroscience, Division of Geriatric Medicine, UPRES EA4638, UNAM, Angers University Hospital, France., Rolland Y; Department of Geriatric Medicine, Institut du Vieillissement, University Hospital, INSERM-U1027, Toulouse, France., Beauchet O; Department of Neuroscience, Division of Geriatric Medicine, UPRES EA4638, UNAM, Angers University Hospital, France.
Jazyk:	angličtina
Zdroj:	The journals of gerontology. Series A, Biological sciences and medical sciences [J Gerontol A Biol Sci Med Sci] 2015 Jan; Vol. 70 (1), pp. 97-101. Date of Electronic Publication: 2014 Aug 23.
DOI:	10.1093/gerona/glu133
Abstrakt:	Background: Vitamin K is involved in brain physiology, suggesting that its deficiency induces cognitive decline. Our objective was to determine whether using vitamin K antagonists (VKAs) was associated with cognitive impairment among geriatric patients. Methods: Two hundred sixty-seven older patients (mean, 83.4 ± 8.1 years; 56.9% female) were categorized according to cognitive impairment (ie, Mini-Mental State Examination ≤ 25). The regular use of VKAs was sought by questioning the patients, relatives, and family physicians. Age, gender, body mass index, comorbidity burden, mood and executive functioning, history of atrial fibrillation, ischemic stroke, intracranial hemorrhage and transient ischemic attack, use of other anticoagulants and antiplatelet medications, and severe renal failure were used as potential confounders. Results: Compared with participants without cognitive impairment (n = 70), those with Mini-Mental State Examination ≤ 25 used more frequently VKAs (p = .038). The risk of cognitive impairment was 15% higher with VKAs, specifically with fluindione. Using VKAs was independently associated with cognitive impairment (fully adjusted odds ratio = 17.4 [95% CI: 1.4-224.2], p = .028). Conclusions: We found more frequent cognitive impairment associated with the use of VKAs, specifically fluindione, among geriatric patients. (© The Author 2014. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu